4D Molecular Therapeutics, Inc. (FDMT) Stock

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company specializing in the development of product candidates utilizing adeno-associated virus vectors. Focused on ophthalmology, cardiology, and pulmonology, the company's portfolio includes several gene therapy candidates currently in clinical trials. These include 4D-125, undergoing Phase 1/2 trials for X-linked retinitis pigmentosa; 4D-110, also in Phase 1/2 trials targeting choroideremia; and 4D-310, advancing through Phase 1/2 trials for Fabry disease. Additionally, 4D Molecular Therapeutics has two investigational new drug (IND) candidates: 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease.

Founded in 2013 and headquartered in Emeryville, California, 4D Molecular Therapeutics collaborates extensively through research agreements with leading entities like uniQure, CRF, Roche, and CFF. These collaborations bolster the company's capabilities in advancing novel gene therapy approaches to address critical unmet medical needs. Leveraging its expertise in AAV vectors, 4D Molecular Therapeutics aims to pioneer transformative treatments that harness the potential of gene therapy to provide durable benefits to patients.

The company's strategic focus on therapeutic areas with high medical necessity underscores its commitment to developing innovative solutions. By targeting genetic diseases affecting vision, heart function, and pulmonary health, 4D Molecular Therapeutics aims to bring new hope to patients and healthcare providers alike. With a robust pipeline and strong research collaborations, the company continues to push the boundaries of gene therapy, aiming to deliver impactful therapies to improve patient outcomes globally.

Driven by a mission to advance the field of gene therapy, 4D Molecular Therapeutics remains dedicated to translating cutting-edge science into meaningful treatments. Through its clinical programs and collaborative efforts, the company strives to redefine the future of medicine and make a lasting impact on the lives of those affected by genetic disorders.